Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II study of targeting trastuzumab resistant HER2+ breast cancer using INB03 as part of combination therapy with Lapatinib

Trial Profile

A Phase II study of targeting trastuzumab resistant HER2+ breast cancer using INB03 as part of combination therapy with Lapatinib

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Pegipanermin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors INmune Bio

Most Recent Events

  • 11 May 2020 According to an INmune Bio media release, the company announced presentation of a pre-clinical study at the New York Academy of Science Frontiers in Cancer Immunotherapy 2020 demonstrating the combination of INB03 with lapatinib reverses resistance to therapy in trastuzumab resistant HER2+ breast cancer. The study work lays the groundwork for and provides rational for use of INB03 and Lapatinib in this upcoming Phase II trial.
  • 11 Mar 2020 According to an INmune Bio media release, the company expects to enroll first patient in this study in mid-2020.
  • 20 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top